What is B. Riley’s Estimate for CGTX FY2024 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at B. Riley issued their FY2024 EPS estimates for Cognition Therapeutics in a report released on Tuesday, November 26th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.62) per share for the year. B. Riley has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share. B. Riley also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.25) EPS and Q4 2025 earnings at ($0.27) EPS.

Several other research firms have also recently weighed in on CGTX. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday. Chardan Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Stock Down 1.6 %

Shares of NASDAQ CGTX opened at $0.40 on Thursday. The company has a market capitalization of $16.53 million, a PE ratio of -0.41 and a beta of 1.34. The stock’s 50 day moving average price is $0.47 and its 200-day moving average price is $1.11. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. CM Management LLC lifted its holdings in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. Virtu Financial LLC bought a new position in Cognition Therapeutics in the 3rd quarter worth approximately $27,000. Finally, Bangor Savings Bank grew its stake in Cognition Therapeutics by 41.6% in the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.